UA104031C2 - Диференціація мезенхімальних стовбурових клітин - Google Patents
Диференціація мезенхімальних стовбурових клітинInfo
- Publication number
- UA104031C2 UA104031C2 UAA201200493A UAA201200493A UA104031C2 UA 104031 C2 UA104031 C2 UA 104031C2 UA A201200493 A UAA201200493 A UA A201200493A UA A201200493 A UAA201200493 A UA A201200493A UA 104031 C2 UA104031 C2 UA 104031C2
- Authority
- UA
- Ukraine
- Prior art keywords
- differentiation
- stem cells
- polypeptide
- mesenchimal stem
- mesenchimal
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title abstract 2
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000001612 chondrocyte Anatomy 0.000 abstract 1
- 230000002648 chondrogenic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22529309P | 2009-07-14 | 2009-07-14 | |
| PCT/US2010/041850 WO2011008773A2 (en) | 2009-07-14 | 2010-07-13 | Mesenchymal stem cell differentiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA104031C2 true UA104031C2 (uk) | 2013-12-25 |
Family
ID=43450138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201200493A UA104031C2 (uk) | 2009-07-14 | 2010-07-13 | Диференціація мезенхімальних стовбурових клітин |
Country Status (30)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010273570B2 (en) * | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CN110198447B (zh) | 2011-11-08 | 2022-01-04 | 韩国电子通信研究院 | 用于共享候选者列表的方法和装置 |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| WO2014004465A1 (en) | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| JO3564B1 (ar) * | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| CA2904160C (en) | 2013-03-15 | 2022-08-23 | The California Institute For Biomedical Research | Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis |
| FI3143026T3 (fi) | 2014-05-13 | 2024-10-10 | Novartis Ag | Yhdisteitä ja koostumuksia kondrogeneesin indusoimiseksi |
| CN104840486A (zh) * | 2015-04-30 | 2015-08-19 | 北京益诺勤生物技术有限公司 | 一种组合物及其应用、制剂 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR20190084287A (ko) | 2016-11-14 | 2019-07-16 | 노파르티스 아게 | 연골 손상 및 관절염 치료 방법 및 조성물 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| US12257243B2 (en) | 2018-12-06 | 2025-03-25 | Novartis Ag | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
| CN113015736B (zh) * | 2018-12-06 | 2024-06-21 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物 |
| CN109432128A (zh) * | 2018-12-07 | 2019-03-08 | 卡替（上海）生物技术股份有限公司 | 牙髓间充质干细胞在银屑病治疗中的应用 |
| KR102246582B1 (ko) * | 2019-04-03 | 2021-04-30 | 이화여자대학교 산학협력단 | 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| WO1999055869A1 (en) | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
| EP1078046A4 (en) | 1998-05-12 | 2005-05-11 | Human Genome Sciences Inc | 97 HUMAN SECRETED PROTEINS |
| AU4643699A (en) * | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
| CA2361849A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| ES2291198T3 (es) * | 1999-07-20 | 2008-03-01 | Genentech, Inc. | Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico. |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US20040249141A1 (en) * | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
| US7687460B2 (en) * | 2000-10-16 | 2010-03-30 | Genentech, Inc, | Methods of treatment using wisp polypeptides |
| US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| CA2464542C (en) | 2001-11-16 | 2015-01-20 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| AU2003270454B2 (en) * | 2002-09-09 | 2010-05-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
| EP1860186B1 (en) * | 2003-03-10 | 2010-11-17 | Japan Science And Technology Agency | Method for distinguishing mesenchymal stem cells using different markers |
| JP3979372B2 (ja) | 2003-09-26 | 2007-09-19 | ブラザー工業株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
| JP5269411B2 (ja) * | 2004-06-21 | 2013-08-21 | ザ クリーブランド クリニック ファウンデーション | 幹細胞をホーミングさせるためのｃｃｒリガンド |
| EP1863340A2 (en) | 2005-03-11 | 2007-12-12 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| JP5139271B2 (ja) | 2005-05-24 | 2013-02-06 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | 培養した造血幹細胞を拡大しかつ分析する方法 |
| US7601501B2 (en) * | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
| JP2010525836A (ja) * | 2007-05-04 | 2010-07-29 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ヒト造血幹細胞のｅｘｖｉｖｏ増殖 |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| AU2010273570B2 (en) * | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
-
2010
- 2010-07-13 AU AU2010273570A patent/AU2010273570B2/en not_active Ceased
- 2010-07-13 PE PE2015002636A patent/PE20160507A1/es not_active Application Discontinuation
- 2010-07-13 MX MX2012000707A patent/MX2012000707A/es active IP Right Grant
- 2010-07-13 EP EP10800425.0A patent/EP2453921B1/en active Active
- 2010-07-13 US US13/383,962 patent/US9139633B2/en active Active
- 2010-07-13 MY MYPI2011006173A patent/MY160951A/en unknown
- 2010-07-13 WO PCT/US2010/041850 patent/WO2011008773A2/en not_active Ceased
- 2010-07-13 KR KR1020127001013A patent/KR101590834B1/ko not_active Expired - Fee Related
- 2010-07-13 UA UAA201200493A patent/UA104031C2/uk unknown
- 2010-07-13 MA MA34524A patent/MA33423B1/fr unknown
- 2010-07-13 KR KR1020167002298A patent/KR20160015403A/ko not_active Withdrawn
- 2010-07-13 ES ES10800425.0T patent/ES2541217T3/es active Active
- 2010-07-13 PL PL10800425T patent/PL2453921T3/pl unknown
- 2010-07-13 CN CN201080031985.4A patent/CN102625830B/zh active Active
- 2010-07-13 PT PT108004250T patent/PT2453921E/pt unknown
- 2010-07-13 PE PE2012000052A patent/PE20120570A1/es not_active Application Discontinuation
- 2010-07-13 BR BR112012000914A patent/BR112012000914B8/pt not_active IP Right Cessation
- 2010-07-13 CN CN201610077451.4A patent/CN105601728B/zh active Active
- 2010-07-13 CA CA2767826A patent/CA2767826C/en active Active
- 2010-07-13 JP JP2012520725A patent/JP5602850B2/ja active Active
- 2010-07-13 SG SG2011095148A patent/SG177318A1/en unknown
- 2010-07-13 EA EA201200118A patent/EA023073B1/ru not_active IP Right Cessation
- 2010-07-13 NZ NZ597306A patent/NZ597306A/en not_active IP Right Cessation
- 2010-07-13 IN IN572DEN2012 patent/IN2012DN00572A/en unknown
- 2010-07-13 KR KR1020177036199A patent/KR20180000337A/ko not_active Ceased
-
2011
- 2011-12-21 TN TNP2011000655A patent/TN2011000655A1/en unknown
-
2012
- 2012-01-05 ZA ZA2012/00078A patent/ZA201200078B/en unknown
- 2012-01-05 IL IL217383A patent/IL217383A/en active IP Right Grant
- 2012-01-12 CL CL2012000091A patent/CL2012000091A1/es unknown
- 2012-01-13 EC ECSP12011604 patent/ECSP12011604A/es unknown
- 2012-01-16 CR CR20120024A patent/CR20120024A/es unknown
- 2012-01-16 CU CU2012000007A patent/CU24042B1/es active IP Right Grant
- 2012-01-19 CO CO12007861A patent/CO6491059A2/es unknown
- 2012-02-09 GT GT201200011A patent/GT201200011A/es unknown
-
2015
- 2015-09-18 US US14/859,126 patent/US10064918B2/en active Active
-
2016
- 2016-08-17 IL IL247310A patent/IL247310B/en active IP Right Grant
-
2018
- 2018-08-21 US US16/106,893 patent/US10555990B2/en active Active
-
2019
- 2019-12-20 US US16/723,424 patent/US11241482B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA104031C2 (uk) | Диференціація мезенхімальних стовбурових клітин | |
| NZ591146A (en) | Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills | |
| IN2012DN02645A (cg-RX-API-DMAC7.html) | ||
| MY175979A (en) | Certain chemical entities, compositions and methods | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| WO2012047733A3 (en) | Treatment of acne by conditioned media | |
| AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
| MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MY184914A (en) | Methods of administering pirfenidone theraphy | |
| MX2011010908A (es) | Anticuerpos anti-tnf-alfa y sus usos. | |
| SG10201805198TA (en) | 18f - fluciclovine compositions in citrate buffers | |
| MX2019006519A (es) | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. | |
| EP4276180A3 (en) | Clostridium histolyticum enzyme | |
| WO2009049284A3 (en) | Compositions and methods for improved glycoprotein sialylation | |
| MX2010008555A (es) | Bacteria recombinante con sistema de secrecion de hemolisina de e-coli y expresion incrementada y/o secrecion de hiya. proceso de elaboracion y usos de la misma. | |
| IN2012DN02210A (cg-RX-API-DMAC7.html) | ||
| NZ707829A (en) | Thermally reactive thermoplastic intermediate product and method of manufacturing thereof | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| WO2011073925A3 (en) | C. histolyticum recombinant collagenases and method for the manufacture thereof | |
| MX2011010359A (es) | Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida. | |
| MX2011012623A (es) | Construcciones de casb7439. | |
| MX2016000480A (es) | Composiciones farmaceuticas de pancreatina de alta potencia. | |
| MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
| MX2011009338A (es) | 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3. | |
| AR077204A1 (es) | Bacterias etanologenicas recombinantes |